Buprenorphine for Medication-Assisted Treatment of Opioid Use Disorder in Pregnancy: Relationship to Neonatal Opioid Withdrawal Syndrome

Niraj R Chavan, Kristin B Ashford, Amanda T Wiggins, Michelle R Lofwall, Agatha S Critchfield, Niraj R Chavan, Kristin B Ashford, Amanda T Wiggins, Michelle R Lofwall, Agatha S Critchfield

Abstract

Objective To examine the relationship between antepartum buprenorphine dose for medication-assisted treatment (MAT) of opioid use disorder (OUD) and incident neonatal opioid withdrawal syndrome (NOWS). Study Design We performed a prospective cohort study of pregnant women with a singleton gestation diagnosed with OUD and receiving buprenorphine for MAT at a tertiary care academic institution from July 2015 to January 2017. We divided the study cohort into two groups-pregnancies with versus without NOWS. Substance abuse patterns in pregnancy, maternal, and neonatal clinical outcomes were compared. Results The incidence of NOWS was 31.11% ( n = 28/90) in our study cohort. Pregnancies with NOWS had a significantly higher rate of benzodiazepine positive urine tests and number of positive urine drug screen (UDS) results for illicit opioids. The group without NOWS had significantly higher number of patients with an appropriate UDS result at delivery through postpartum. Rates of neonatal intensive care unit (NICU) admission, length of NICU stay, and maximum Finnegan score were significantly higher in the group with NOWS. Neither the initial (10.6 ± 5.2 versus 10.3 ± 4.8 mg, p = 0.80) nor the final buprenorphine doses (13.3 ± 5.1 versus 13.0 ± 4.6 mg, p = 0.81) were significantly different between study groups. Conclusion The occurrence of NOWS was not related to buprenorphine dose used for MAT.

Keywords: buprenorphine; medication assisted treatment (MAT); neonatal opioid withdrawal syndrome (NOWS); opioid use disorder (OUD).

Conflict of interest statement

Conflicts of Interest Dr. Lofwall reports grants and consulting fees from Braeburn Pharmaceuticals, consulting fees from Indivior, and honorarium from PCM Scientific, outside the submitted work.

References

    1. Jones H E, Kaltenbach K, Heil S H et al.Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363(24):2320–2331.
    1. Kandall S R, Albin S, Gartner L M, Lee K-S, Eidelman A, Lowinson J. The narcotic-dependent mother: fetal and neonatal consequences. Early Hum Dev. 1977;1(02):159–169.
    1. Messinger D S, Bauer C R, Das A et al.The maternal lifestyle study: cognitive, motor, and behavioral outcomes of cocaine-exposed and opiate-exposed infants through three years of age. Pediatrics. 2004;113(06):1677–1685.
    1. Lifschitz M H, Wilson G S, Smith E O, Desmond M M. Factors affecting head growth and intellectual function in children of drug addicts. Pediatrics. 1985;75(02):269–274.
    1. Women ACoHCfU.ACOG Committee Opinion No. 524: opioid abuse, dependence, and addiction in pregnancy Obstet Anesthes Dig 20133379–80.
    1. Center for Substance Abuse Treatment. Improving Treatment for Drug-Exposed Infants: Substance Abuse and Mental Health Services Administration (US); 1993. Report No.: (SMA) 93–2011.. Accessed November 28, 2017
    1. Patrick S W, Schumacher R E, Benneyworth B D, Krans E E, McAllister J M, Davis M M. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA. 2012;307(18):1934–1940.
    1. Jones H E, O'Grady K E, Malfi D, Tuten M. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict. 2008;17(05):372–386.
    1. Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy. Effects and management. Obstet Gynecol Clin North Am. 1998;25(01):139–151.
    1. Dryden C, Young D, Hepburn M, Mactier H. Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. BJOG. 2009;116(05):665–671.
    1. Cleary B J, Donnelly J, Strawbridge J et al.Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis. Addiction. 2010;105(12):2071–2084.
    1. Jansson L M, Velez M. Neonatal abstinence syndrome. Curr Opin Pediatr. 2012;24(02):252–258.
    1. Bakstad B, Sarfi M, Welle-Strand G K, Ravndal E. Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. A national prospective study. Eur Addict Res. 2009;15(03):128–134.
    1. Finnegan L P, Connaughton J F, Jr, Kron R E, Emich J P.Neonatal abstinence syndrome: assessment and management Addict Dis 19752(1-2):141–158.
    1. Jansson L M, Velez M, Harrow C. The opioid-exposed newborn: assessment and pharmacologic management. J Opioid Manag. 2009;5(01):47–55.
    1. Fudala P J, Bridge T P, Herbert S et al.Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949–958.
    1. Johnson R E, Jones H E, Fischer G.Use of buprenorphine in pregnancy: patient management and effects on the neonate Drug Alcohol Depend 200370(2, Suppl)S87–S101.
    1. Jones E S, Moore B A, Sindelar J L, O'Connor P G, Schottenfeld R S, Fiellin D A.Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients Drug Alcohol Depend 200999(1-3):132–140.
    1. Jones H E. Practical considerations for the clinical use of buprenorphine. Sci Pract Perspect. 2004;2(02):4–20.
    1. Jones H E, Finnegan L P, Kaltenbach K. Methadone and buprenorphine for the management of opioid dependence in pregnancy. Drugs. 2012;72(06):747–757.
    1. Jones H E, Johnson R E, Jasinski D R et al.Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005;79(01):1–10.
    1. Jones H E, Fischer G, Heil S H et al.Maternal Opioid Treatment: Human Experimental Research (MOTHER)--approach, issues and lessons learned. Addiction. 2012;107 01:28–35.
    1. Kakko J, Heilig M, Sarman I.Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series Drug Alcohol Depend 200896(1-2):69–78.
    1. Welle-Strand G K, Skurtveit S, Jones H Eet al.Neonatal outcomes following in utero exposure to methadone or buprenorphine: a National Cohort Study of opioid-agonist treatment of Pregnant Women in Norway from 1996 to 2009 Drug Alcohol Depend 2013127(1-3):200–206.
    1. Fischer G, Ortner R, Rohrmeister K et al.Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction. 2006;101(02):275–281.
    1. Lejeune C, Simmat-Durand L, Gourarier L, Aubisson S; Groupe d'Etudes Grossesse et Addictions (GEGA).Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution Drug Alcohol Depend 20068203250–257.
    1. Choo R E, Huestis M A, Schroeder J R, Shin A S, Jones H E. Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. Drug Alcohol Depend. 2004;75(03):253–260.
    1. Winklbaur B, Baewert A, Jagsch R et al.Association between prenatal tobacco exposure and outcome of neonates born to opioid-maintained mothers. Implications for treatment. Eur Addict Res. 2009;15(03):150–156.
    1. Jones H E, Dengler E, Garrison A et al.Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug Alcohol Depend. 2014;134:414–417.
    1. Hoenig J M, Heisey D M. The abuse of power: the pervasive fallacy of power calculations for data analysis. Am Stat. 2001;55:19–24.
    1. Kacinko S L, Jones H E, Johnson R E, Choo R E, Huestis M A. Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes. Clin Pharmacol Ther. 2008;84(05):604–612.
    1. Hytinantti T, Kahila H, Renlund M, Järvenpää A L, Halmesmäki E, Kivitie-Kallio S. Neonatal outcome of 58 infants exposed to maternal buprenorphine in utero. Acta Paediatr. 2008;97(08):1040–1044.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel